Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes

Aims: To assess the potential direct effects of the integrase strand-transfer inhibitors (INsTIs) dolutegravir, bictegravir, and raltegravir, drugs used as treatment for people living with human immunodeficiency virus (PLWH), on human adipose cells. Main methods: Drugs were added to the differentiat...

ver descrição completa

Detalhes bibliográficos
Autores: Domingo, P, Quesada-Lopez, T, Villarroya, J, Cairo, M, Gutierrez, MD, Mateo, MG, Mur, I, Corbacho, N, Domingo, JC, Villarroya, F, Giralt, M
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2022
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositório:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p15607
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15607
https://ddd.uab.cat/record/280874
Access Level:Acceso aberto
Palavra-chave:Fat
Adipocyte
Anti-retroviral treatment
HIV integrase inhibitors
Adipokine
Cytokine
id ES_01bb4256411a8a5f91b59fa41bca1c40
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p15607
network_acronym_str ES
network_name_str España
repository_id_str
spelling Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytesDomingo, PQuesada-Lopez, TVillarroya, JCairo, MGutierrez, MDMateo, MGMur, ICorbacho, NDomingo, JCVillarroya, FGiralt, MFatAdipocyteAnti-retroviral treatmentHIV integrase inhibitorsAdipokineCytokineAims: To assess the potential direct effects of the integrase strand-transfer inhibitors (INsTIs) dolutegravir, bictegravir, and raltegravir, drugs used as treatment for people living with human immunodeficiency virus (PLWH), on human adipose cells. Main methods: Drugs were added to the differentiation medium of human Simpson-Golabi-Behmel syndrome (SGBS) adipose cells and morphological adipogenesis was monitored for 10 days. Also, adipocytes were exposed to drugs following differentiation (day 14). The gene expression levels of selected adipogenesis markers, adipocyte metabolism markers, adipokines, and cytokines were determined by quantitative-reverse transcription polymerase-chain reaction. The release of adiponectin and leptin into the culture medium was measured using specific enzyme-linked immunosorbent assay, and release of interleukin-6 and chemokine (C-C motif) ligand-2 using Multiplex assays. Key findings: Overall morphological adipogenesis was unaltered by INsTIs. The expression of adipogenesis marker genes (peroxisome proliferator-activated receptor-gamma and lipoprotein lipase) was slightly reduced in dolutegravir-treated differentiating adipocytes. Bictegravir repressed gene expression and the release of pro-inflammatory cytokines in differentiating adipocytes. Dolutegravir and raltegravir increased interleukin-6 gene expression, but only dolutegravir increased interleukin-6 release. Dolutegravir repressed adiponectin expression and release in differentiating adipocytes and had a similar but milder effect on leptin. Drug treatment of mature adipocytes reduced adiponectin gene expression in response to dolutegravir. Significance: The INsTIs studied do not have a significant effect on human adipose cell differentiation but exert distinct effects on gene expression and secretion of adipokines and cytokines. These findings will help understand and manage the effects of INsTI-containing treatments on body weight and metabolic dysregulation in PLWH.PERGAMON-ELSEVIER SCIENCE LTD2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15607https://ddd.uab.cat/record/280874LIFE SCIENCESISSN: 00243205ISSNe: 18790631reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p156072026-06-14T12:41:47Z
dc.title.none.fl_str_mv Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes
title Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes
spellingShingle Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes
Domingo, P
Fat
Adipocyte
Anti-retroviral treatment
HIV integrase inhibitors
Adipokine
Cytokine
title_short Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes
title_full Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes
title_fullStr Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes
title_full_unstemmed Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes
title_sort Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes
dc.creator.none.fl_str_mv Domingo, P
Quesada-Lopez, T
Villarroya, J
Cairo, M
Gutierrez, MD
Mateo, MG
Mur, I
Corbacho, N
Domingo, JC
Villarroya, F
Giralt, M
author Domingo, P
author_facet Domingo, P
Quesada-Lopez, T
Villarroya, J
Cairo, M
Gutierrez, MD
Mateo, MG
Mur, I
Corbacho, N
Domingo, JC
Villarroya, F
Giralt, M
author_role author
author2 Quesada-Lopez, T
Villarroya, J
Cairo, M
Gutierrez, MD
Mateo, MG
Mur, I
Corbacho, N
Domingo, JC
Villarroya, F
Giralt, M
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Fat
Adipocyte
Anti-retroviral treatment
HIV integrase inhibitors
Adipokine
Cytokine
topic Fat
Adipocyte
Anti-retroviral treatment
HIV integrase inhibitors
Adipokine
Cytokine
description Aims: To assess the potential direct effects of the integrase strand-transfer inhibitors (INsTIs) dolutegravir, bictegravir, and raltegravir, drugs used as treatment for people living with human immunodeficiency virus (PLWH), on human adipose cells. Main methods: Drugs were added to the differentiation medium of human Simpson-Golabi-Behmel syndrome (SGBS) adipose cells and morphological adipogenesis was monitored for 10 days. Also, adipocytes were exposed to drugs following differentiation (day 14). The gene expression levels of selected adipogenesis markers, adipocyte metabolism markers, adipokines, and cytokines were determined by quantitative-reverse transcription polymerase-chain reaction. The release of adiponectin and leptin into the culture medium was measured using specific enzyme-linked immunosorbent assay, and release of interleukin-6 and chemokine (C-C motif) ligand-2 using Multiplex assays. Key findings: Overall morphological adipogenesis was unaltered by INsTIs. The expression of adipogenesis marker genes (peroxisome proliferator-activated receptor-gamma and lipoprotein lipase) was slightly reduced in dolutegravir-treated differentiating adipocytes. Bictegravir repressed gene expression and the release of pro-inflammatory cytokines in differentiating adipocytes. Dolutegravir and raltegravir increased interleukin-6 gene expression, but only dolutegravir increased interleukin-6 release. Dolutegravir repressed adiponectin expression and release in differentiating adipocytes and had a similar but milder effect on leptin. Drug treatment of mature adipocytes reduced adiponectin gene expression in response to dolutegravir. Significance: The INsTIs studied do not have a significant effect on human adipose cell differentiation but exert distinct effects on gene expression and secretion of adipokines and cytokines. These findings will help understand and manage the effects of INsTI-containing treatments on body weight and metabolic dysregulation in PLWH.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15607
https://ddd.uab.cat/record/280874
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15607
https://ddd.uab.cat/record/280874
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv PERGAMON-ELSEVIER SCIENCE LTD
publisher.none.fl_str_mv PERGAMON-ELSEVIER SCIENCE LTD
dc.source.none.fl_str_mv LIFE SCIENCES
ISSN: 00243205
ISSNe: 18790631
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402604716425216
score 15,811543

Registros relacionados